share_log

迈威生物(688062.SH):迈卫健获得国家药品监督管理局批准上市

Maiwei Biotech (688062.SH): Maiweijian was approved for listing by the State Drug Administration

Gelonghui Finance ·  Apr 3 05:07

Gelonghui, April 3 | Maiwei Biology (688062.SH) announced that the marketing application for desulumab injection (9MW0321) submitted by Jiangsu Taikang Biomedical Co., Ltd., a wholly-owned subsidiary of the company, was approved by the State Drug Administration to treat bone giant cell tumors that cannot be surgically resected or may cause serious functional impairment, including adults and young patients with mature skeletal development (defined as at least 1 mature long bone and body weight ≥45 kg). It is the first Agave (desumab injection, 120mg) biosimilar to the marketing approval in China medicine. MyHealth is a recombinant all-human anti-RANKL monoclonal antibody injection, which is a biosimilar of Agavi.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment